Latest in Research & Development

Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody

The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development

Find out more

Thermo Fisher Scientific partners with NVIDIA to advance laboratory automation with AI

The pair will leverage NVIDIA's AI platform to progressively increase the automation, accuracy and speed of laboratories, helping scientists reduce manual steps and accelerate...
See more

FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design

The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline

Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive

Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage

Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic

Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform

Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies

Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies

Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi

The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites

One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research

GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month

Eli Lilly pays $55m for obesity drug research collab with Nimbus Therapeutics

The pair have entered into a multi-year research collaboration to develop a novel oral treatment for obesity and other metabolic diseases

LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener

Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more

Latest posts in Research & Development

LoQus23 Therapeutics nominates new oral drug candidate for Huntington's Disease

The biotech company has put forward LQT-23, a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ with a unique mechanism of action with potential to slow or stop the progression of HD

Acesion Pharma begins Phase II cardiac arrythmia trial

The Phase II trial of AP31969 in patients with atrial fibrillation will assess the safety and efficacy of the oral SK ion channel inhibitor AP31969 in patients across Europe

Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes

Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes

Vanda Pharmaceuticals secures FDA approval for motion sickness treatment NEREUS

The US FDA has approved Vanda Pharmaceuticals’ NEREUS (tradipitant) for the prevention of vomiting induced by motion, marking a historic regulatory milestone and introducing the first novel pharmacological option for motion sickness in more than four decades

A new era in diabetes: five biotech companies moving past daily insulin injections

From cell-encapsulation platforms and islet transplantation breakthroughs to next-generation GLP-1 combinations and connected insulin delivery, a new wave of biotech innovation is reshaping the future of diabetes treatment and investment

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells

When science meets security: the future of small molecule outsourcing

Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence competitiveness for years to come

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media

Groundbreaking research suggests plastic waste could be used to make anti-cancer drugs

A discovery made by the University of St Andrews has revealed a way to turn ordinary household plastic waste into the building block for anti-cancer treatments

Sponsor content

Titan Enterprises highly commended for Manufacturer of the Year at industry awards

Recognition reflects the company’s investment in innovation and precision flow measurement

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact

Work safely with hazardous substances – new Asecos catalogue available now

Asecos cabinets help minimise risks when storing flammable substances

Redefining QP training for today’s professionals

How NSF is making specialist learning more flexible and accessible

NSF’s QP training program combines technical skill with personalised guidance

A mentoring-led approach supporting delegates through every stage of the QP journey

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment

Abzena advances ADC development with ThioBridge conjugation technology

Next-generation conjugation delivers greater stability, potency and control for targeted cancer therapeutics

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification

Flowchem teaching manual now available to download

Guide offers step-by-step instructions for ten reactions including Nobel Prize-winning examples

Cut Argon use and costs with Shimadzu’s ICPMS-2040/2050

New Mini-Torch System offers precision analysis with 40% less Argon

Featured companies

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life... PCI Pharma Services: Your bridge between life-changing therapies and patients. Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway for small-molecule and peptide drug... CARBOGEN AMCIS is a global Contract Development and Manufacturing Organization (CDMO) providing drug development and commercialization services to the pharmaceutical and...
See more